{"id":"nadifloxacin","rwe":[{"pmid":"40983416","year":"2025","title":"Resonance-matched terahertz metamaterials integrated with IRFE-MLR framework enabling specificity-enhanced detection of trace pefloxacin.","finding":"","journal":"Analytica chimica acta","studyType":"Clinical Study"},{"pmid":"40832589","year":"2025","title":"Melanonychia: A Challenging Green Nail Syndrome Case Report.","finding":"","journal":"Clinical case reports","studyType":"Clinical Study"},{"pmid":"40678879","year":"2025","title":"Chiral Separation and Molecular Simulation of Five Quinolones on a Bonded Amylose[(S)-α-Methylbenzyl Carbamate] Column (CHIRALPAK IH) and the Elucidation of Its Recognition Mechanism.","finding":"","journal":"Chirality","studyType":"Clinical Study"},{"pmid":"40009894","year":"2025","title":"Historical distribution and multi-dimensional environmental risk assessments of antibiotics in coastal sediments affected by land-based human activities.","finding":"","journal":"Marine pollution bulletin","studyType":"Clinical Study"},{"pmid":"39087744","year":"2024","title":"Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes.","finding":"","journal":"The Journal of dermatology","studyType":"Clinical Study"}],"tags":[{"label":"nadifloxacin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D10AF05","category":"atc"},{"label":"Active","category":"status"},{"label":"Acne vulgaris","category":"indication"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase II Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nadixa","offLabel":[],"synonyms":["OPC 7251","OPC-7251","nadixa","jinofloxacin","nadifloxacin"],"timeline":[],"approvals":[],"brandName":"Nadixa","ecosystem":[{"indication":"Acne vulgaris","otherDrugs":[{"name":"adapalene","slug":"adapalene","company":"Galderma Labs Lp"},{"name":"ammonia","slug":"ammonia","company":""},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azelaic acid","slug":"azelaic-acid","company":"Allergan"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"nadifloxacin","explanation":"Think of Nadixa like a key that locks up a bacterial cell's ability to make copies of itself. By blocking these enzymes, Nadixa prevents the bacteria from multiplying and eventually kills them. This helps to clear up acne by reducing the number of bacteria on the skin.","oneSentence":"Nadixa works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription.","technicalDetail":"Nadixa exerts its antibacterial effects by binding to the ATP-binding sites of DNA gyrase and topoisomerase IV, thereby inhibiting the enzymes' ability to catalyze the relaxation of supercoiled DNA and the unwinding of double-stranded DNA."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1864","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NADIFLOXACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NADIFLOXACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:52:29.990206","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:44:18.382938+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"clindamycin","drugSlug":"clindamycin","fdaApproval":"1970-02-22","patentExpiry":"Sep 22, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"erythromycin","drugSlug":"erythromycin","fdaApproval":"1964-06-24","genericCount":39,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"chloramphenicol","drugSlug":"chloramphenicol","fdaApproval":"1950-12-08","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"meclocycline","drugSlug":"meclocycline","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sulfacetamide","drugSlug":"sulfacetamide","fdaApproval":"1945-09-12","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"minocycline","drugSlug":"minocycline","fdaApproval":"1971-06-30","patentExpiry":"Sep 8, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"nadifloxacin","indications":{"approved":[{"name":"Acne vulgaris","source":"DrugCentral","snomedId":88616000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clindamycin","brandName":"clindamycin","genericName":"clindamycin","approvalYear":"1970","relationship":"same-class"},{"drugId":"erythromycin","brandName":"erythromycin","genericName":"erythromycin","approvalYear":"1964","relationship":"same-class"},{"drugId":"chloramphenicol","brandName":"chloramphenicol","genericName":"chloramphenicol","approvalYear":"1950","relationship":"same-class"},{"drugId":"meclocycline","brandName":"meclocycline","genericName":"meclocycline","approvalYear":"","relationship":"same-class"},{"drugId":"sulfacetamide","brandName":"sulfacetamide","genericName":"sulfacetamide","approvalYear":"1945","relationship":"same-class"},{"drugId":"minocycline","brandName":"minocycline","genericName":"minocycline","approvalYear":"1971","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00202891","phase":"PHASE4","title":"Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":["Pyoderma"],"enrollment":0,"completionDate":"2007-09"},{"nctId":"NCT00219570","phase":"PHASE4","title":"Dalacin-T Gel Post Approval Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-01","conditions":["Acne Vulgaris"],"enrollment":134,"completionDate":"2005-06"},{"nctId":"NCT00869492","phase":"PHASE3","title":"Comparison of Nadifloxacin Cream Alone and With Benzoyl Peroxide Solution in the Treatment of Acne","status":"UNKNOWN","sponsor":"Marmara University","startDate":"2008-08","conditions":["Acne Vulgaris"],"enrollment":90,"completionDate":"2009-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"007854","UNII":"6CL9Y5YZEQ","CHEBI":"CHEBI:31889","INN_ID":"6702","UMLSCUI":"C0286402","ChEMBL_ID":"CHEMBL363449","KEGG_DRUG":"D01147","DRUGBANK_ID":"DB12447","PUBCHEM_CID":"4410","SNOMEDCT_US":"698260001","MESH_SUPPLEMENTAL_RECORD_UI":"C062127"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"6.04 hours","clearance":"0.54 mL/min/kg","volumeOfDistribution":"0.25 L/kg"},"publicationCount":111,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D10AF05","allCodes":["D10AF05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 8","pmid":"40983416","title":"Resonance-matched terahertz metamaterials integrated with IRFE-MLR framework enabling specificity-enhanced detection of trace pefloxacin.","journal":"Analytica chimica acta"},{"date":"2025 Aug","pmid":"40832589","title":"Melanonychia: A Challenging Green Nail Syndrome Case Report.","journal":"Clinical case reports"},{"date":"2025 Aug","pmid":"40678879","title":"Chiral Separation and Molecular Simulation of Five Quinolones on a Bonded Amylose[(S)-α-Methylbenzyl Carbamate] Column (CHIRALPAK IH) and the Elucidation of Its Recognition Mechanism.","journal":"Chirality"},{"date":"2025 May","pmid":"40009894","title":"Historical distribution and multi-dimensional environmental risk assessments of antibiotics in coastal sediments affected by land-based human activities.","journal":"Marine pollution bulletin"},{"date":"2024 Sep","pmid":"39087744","title":"Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes.","journal":"The Journal of dermatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nadifloxacin is a small molecule that inhibits bacterial DNA gyrase, a mechanism that is classified as an inhibitor. It has been studied in clinical trials for the treatment of acne vulgaris, including a comparison of its effectiveness alone and in combination with benzoyl peroxide.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:44:18.382938+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}